-90%

est. 2Y upside i

HealthcareHardwareSeed

Desktop DNA Printer. The Nespresso Machine for DNA.

Rank

#1992

Sector

Biotechnology, Life Sciences, Hardware

Est. Liquidity

~7Y

Data Quality

Data: Low

Kilobaser presents a high-risk, moderate-upside equity opportunity, driven by innovative technology and early revenue traction, but significantly challenged by limited funding and formidable incumbent competition.

Last updated: February 16, 2026

Bull (15%)+400%

Kilobaser leverages its strong initial revenue and innovative technology to secure a significant Series A, rapidly expands its product line and market share, leading to a high-multiple acquisition.

Base (40%)+75%

Kilobaser continues to grow steadily within its niche, maintaining profitability but facing ongoing competitive pressure, resulting in a modest acquisition or sustained operation as a smaller, specialized company.

Bear (45%)-90%

Despite initial revenue, Kilobaser struggles to scale against well-funded incumbents, runs out of capital, or its technology is commoditized, leading to a significant loss of value or shutdown.

Est. time to liquidity~7.0 years
View all 6 open roles at Kilobaser →

Last updated: March 10, 2026

Community

Valuation Sentiment

Our model estimates -90% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.